- Achieves EBITDA Positive for first full quarter in Company
history
- Decreases operating expenses by 52% year-over-year
- Improves Gross Margin (non
IFRS)1 by 1,100
basis points year-over-year
- Quarterly conference call scheduled for Nov 16, 2023 at 5 pm
ET
TORONTO, Nov. 16,
2023 /CNW/ - Newtopia Inc. ("Newtopia" or the
"Company") (TSXV: NEWU) (OTCQB: NEWUF), a tech-enabled whole
health platform creating sustainable healthy habits that prevent,
slow, and reverse chronic disease, today announced its third
quarter 2023 financial results, operational highlights and the
filing of the Company's quarterly financial statements. These
results pertain to the three and nine months ended September 30, 2023. All amounts are expressed in
Canadian dollars, unless otherwise noted.
Third Quarter 2023 Financial Highlights (vs. Q3
2022):
- Revenue of $2.43 million, as
compared to $2.65 million.
- Gross profit margin1 of 66%, as compared to
55%.
"Newtopia's Q3 2023 was all about profitability, as we
delivered our Company's first EBITDA-positive quarter", said
Jeff Ruby, Founder and CEO of
Newtopia. "These results are even more impressive in light of the
difficult macroeconomic backdrop, and I could not be prouder of our
entire team for their efforts in reaching this Company milestone a
full quarter ahead of our internal plan. While revenues remained
soft in line with market conditions, by keeping our operating
expenses in check, we were able to achieve bottom line
profitability, making Newtopia one of the very few profitable
health technology companies."
Ruby continued, "During the quarter, we maintained our key
innovator clients while pursuing new initiatives in both the U.S.
and Canada. Regarding the former, as previously announced,
Newtopia has launched an innovative Health Coaching Project (the
Project) in partnership with a prominent philanthropic foundation,
designed to positively impact chronic disease burden on a regional
basis in the southeastern United
States. The Project has commenced with patients of a large
primary care provider with nearly 20 locations in two counties who
have been identified through biometric and diagnostic data
indicating they suffer from type-2 diabetes or hypertension and
have a corresponding BMI greater than 30. The Project is positioned
to expand to other providers and employers in the region, home to a
population of more than 500,000 people, and offers a blueprint for
the deployment of scalable, value-based primary prevention efforts
with large, national employers, payors and providers across
the United States."
Third Quarter 2023 Financial
Results
Revenue for the three months ended Sep
30, 2023 was $2.43 million,
compared to $2.65 million in the
prior-year period. Enrollment fee revenue, or revenue from Welcome
Kit sales, totaled 7% of revenue for the quarter, compared with 8%
in Q3 2022.
Non-IFRS gross profit for the third quarter 2023 totaled
$1.60 million, as compared to
$1.45 million in the prior-year
period. This calculation consists of Newtopia's revenue less
direct expenses, which include the cost of Welcome Kits sold to new
participants and labor costs associated with hiring and training
the Company's coaching team of Inspirators (health coaches). As a
percentage of revenue, gross profit year to date has totaled 61%,
compared to 50% in the prior-year period.
Operating expenses2 for the three
months ended Sep 30, 2023 totaled
$1.6 million, compared to
$3.3 million in the prior-year period
and $1.8 million in Q2 2023. For the
third quarter, EBITDA3 totaled a gain of
$21 thousand, compared to a loss of
$1.8 million in the prior-year
period and a loss of $0.4 million in
Q2 2023.
The Company ended the third quarter 2023 with approximately
$0.6 million in cash, with additional
access to its revolving line of credit with a Canadian Schedule-1
bank and a previously announced $2.5
million debenture issuance that was extended to September 2024.
2023 Outlook
Newtopia anticipates that the Company will remain EBITDA
positive in the fourth quarter.
Conference Call
The Company will host a conference call today at 5 p.m. Eastern Time to discuss the third quarter
2023 results in further detail. To access the conference call,
please dial (877) 407-3982 (U.S.) or (201) 493-6780 (International)
10 minutes prior to the start time and reference Conference ID
number 13741435. The call will also be available via live webcast
on the investor relations portion of the Company's website located
at investor.newtopia.com.
A replay of the conference call will be available through
December 7, 2023 which can be
accessed by dialing (844) 512-2921 (U.S.) or (412) 317-6671
(International) and entering the passcode 13741435. The webcast
will also be archived on the Company's website.
About Newtopia
Newtopia is a tech-enabled habit change provider focused on
disease prevention and reducing the cost of care for health
insurers. As a provider of whole person care,
we prevent, reverse and slow the
progression of chronic disease while enriching mental health,
resilience and overall human performance. Newtopia's programs
leverage genetic, social and behavioral insights to create
individualized prevention programs with a focus on type 2 diabetes,
heart disease, stroke and weight. With a person-centered approach
that combines virtual care, digital tools, connected devices and
actionable data science, Newtopia delivers sustainable clinical and
financial outcomes. To learn more,
visit newtopia.com, LinkedIn or X.
Forward Looking
Statements
This news release contains forward-looking information and
forward-looking statements, within the meaning of applicable
Canadian securities legislation, and forward looking statements,
within the meaning of applicable United
States securities legislation (collectively,
"forward-looking statements"), which reflects management's
expectations regarding Newtopia's future growth, results from
operations (including, without limitation, future production and
capital expenditures), performance (both operational and financial)
and business prospects and opportunities. Wherever possible, words
such as "predicts", "projects", "targets", "plans", "expects",
"does not expect", "budget", "scheduled", "estimates", "forecasts",
"anticipate" or "does not anticipate", "believe", "intend" and
similar expressions or statements that certain actions, events or
results "may", "could", "would", "might" or "will" be taken, occur
or be achieved, or the negative or grammatical variation thereof or
other variations thereof, or comparable terminology have been used
to identify forward-looking statements. All statements other than
statements of historical fact may be forward- looking information.
Such statements reflect Newtopia's current views and intentions
with respect to future events, based on information available to
Newtopia, and are subject to certain risks, uncertainties, and
assumptions. Material factors or assumptions were applied in
providing forward-looking information. While forward-looking
statements are based on data, assumptions and analyses that
Newtopia believes are reasonable under the circumstances, whether
actual results, performance or developments will meet Newtopia's
expectations and predictions depends on a number of risks and
uncertainties that could cause the actual results, performance and
financial condition of Newtopia to differ materially from its
expectations. Forward-looking statements are not a guarantee and
are based on a number of estimates and assumptions management
believes to be relevant and reasonable, whether actual results,
performance or developments will meet Newtopia's expectations and
predictions depends on a number of risks and uncertainties that
could cause the actual results, performance and financial condition
of Newtopia to differ materially from its expectations. Certain of
the "risk factors" that could cause actual results to differ
materially from Newtopia's forward-looking statements in this press
release include, without limitation: the termination of contracts
by clients, risks related to COVID-19 including various
recommendations, orders and measures of governmental authorities to
try to limit the pandemic, including travel restrictions,
border closures, non-essential business closures, quarantines,
self-isolations, shelters- in-place and social distancing,
disruptions to markets, economic activity, financing, supply chains
and sales channels, and a deterioration of general economic
conditions including a possible national or global recession; and
other general economic, market and business conditions and factors,
including the risk factors discussed or referred to in Newtopia's
disclosure documents, filed with the securities regulatory
authorities in certain provinces of Canada and available at www.sedar.com
including Newtopia's final long form prospectus dated March 30, 2020.
Should any factor affect Newtopia's in an unexpected manner, or
should assumptions underlying the forward-looking information prove
incorrect, the actual results or events may differ materially from
the results or events predicted. Any such forward-looking
information is expressly qualified in its entirety by this
cautionary statement. Moreover, Newtopia does not assume
responsibility for the accuracy or completeness of such
forward-looking information. The forward-looking information
included in this press release is made as of the date of this press
release, and Newtopia undertakes no obligation to publicly update
or revise any forward-looking information, other than as required
by applicable law.
Non-IFRS Financial
Measures
The Company's financial statements are prepared in accordance
with International Financial Reporting Standards ("IFRS").
Management uses certain non-IFRS measures, which are defined in the
appropriate sections of this press release, to better assess the
Company's underlying performance. These measures are reviewed
regularly by management and the Company's Board of Directors in
assessing the Company's performance and in making decisions about
ongoing operations. In addition, we use certain non-IFRS measures
to determine the components of management compensation. We believe
that these measures are also used by investors as an indicator of
the Company's operating performance. Readers are cautioned that
these terms are not recognized IFRS measures and do not have a
standardized meaning under IFRS and should not be construed as
alternatives to IFRS terms, such as net income.
Neither the TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Key Financial Measures and
Schedule of Non-GAAP Reconciliations
Gross Profit Information 1
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
$
|
|
$
|
|
$
|
|
$
|
Revenue
|
2,434,606
|
|
2,653,411
|
|
7,440,297
|
|
8,052,111
|
Cost of
revenue
|
(1,040,987)
|
|
(1,201,016)
|
|
(3,501,369)
|
|
(4,060,793)
|
Gross profit
|
1,393,619
|
|
1,452,395
|
|
3,938,928
|
|
3,991,318
|
Add Amortization of
intangible asset
|
206,514
|
|
-
|
|
619,537
|
|
-
|
Non-IFRS adjusted gross
profit
|
1,600,133
|
|
1,452,395
|
|
4,558,465
|
|
3,991,318
|
|
|
|
|
|
|
|
|
Gross profit
margin
|
57 %
|
|
55 %
|
|
53 %
|
|
50 %
|
Non-IFRS adjusted
gross profit
margin
|
66 %
|
|
55 %
|
|
61 %
|
|
50 %
|
Reconciliation of Total Operating Expenses to Adjusted Operating
Expenses 2
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
$
|
|
$
|
|
$
|
|
$
|
Total
expenses
|
2,167,150
|
|
3,700,414
|
|
7,316,306
|
|
10,098,771
|
Add
(Subtract)
|
|
|
|
|
|
|
|
Share-based
compensation
|
(158,584)
|
|
(140,314)
|
|
(466,887)
|
|
(404,112)
|
Depreciation of
property and
equipment
|
(1,386)
|
|
(11,891)
|
|
(4,965)
|
|
(39,674)
|
Depreciation of
right-of-use asset
|
-
|
|
(46,192)
|
|
-
|
|
(138,579)
|
Interest and accretion
expense
|
(246,556)
|
|
(79,163)
|
|
(593,979)
|
|
(276,884)
|
Interest on lease
obligations
|
(5,221)
|
|
(17,485)
|
|
(26,784)
|
|
(60,747)
|
Finance
charges
|
(145,024)
|
|
(70,269)
|
|
(376,990)
|
|
(147,816)
|
Amortization of
deferred finance
charges
|
(39,710)
|
|
(68,140)
|
|
(107,500)
|
|
(191,910)
|
Foreign exchange loss
(gain)
|
17,302
|
|
5,534
|
|
(36,791)
|
|
28,998
|
Capitalized borrowing
costs
|
-
|
|
-
|
|
-
|
|
67,000
|
Impairment of
right-of-use asset
|
-
|
|
-
|
|
-
|
|
-
|
Loss on extinguishment
of debt
|
(15,336)
|
|
-
|
|
(15,336)
|
|
-
|
Debt
modification
|
6,380
|
|
-
|
|
6,380
|
|
-
|
Gain on settlement of
related party
payable
|
-
|
|
3,111
|
|
7,203
|
|
3,111
|
Adjusted operating
expenses
|
1,579,015
|
|
3,275,605
|
|
5,700,657
|
|
8,938,158
|
EBITDA 3
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
|
2023
|
|
2022
|
|
2023
|
|
2022
|
|
$
|
|
$
|
|
$
|
|
$
|
Non-IFRS adjusted gross
profit
|
1,600,133
|
|
1,452,395
|
|
4,558,465
|
|
3,991,318
|
Adjusted operating
expenses
|
(1,579,015)
|
|
(3,275,605)
|
|
(5,700,657)
|
|
(8,938,158)
|
EBITDA
|
21,118
|
|
(1,823,210)
|
|
(1,142,192)
|
|
(4,946,840)
|
NEWTOPIA INC.
Condensed Interim Consolidated
Statements of Financial Position (Unaudited)
As at September 30, 2023 and
December 31, 2022
(Expressed in Canadian Dollars)
|
|
|
|
|
|
September
30,
|
December 31,
|
|
|
2023
|
2022
|
|
|
$
|
$
|
Assets
|
|
|
|
Current
assets
|
|
|
|
Cash
|
|
575,634
|
345,950
|
Trade and other
receivables
|
|
1,774,627
|
1,557,640
|
Contract
asset
|
|
15,330
|
190,000
|
Prepaid expenses and
deposits
|
|
239,555
|
205,843
|
Inventories
|
|
117,420
|
325,571
|
Deferred
costs
|
|
86,029
|
76,269
|
|
|
2,808,595
|
2,701,273
|
|
|
|
|
Property and
equipment
|
|
5,635
|
8,052
|
Intangible
asset
|
|
2,615,826
|
3,235,363
|
|
|
5,430,056
|
5,944,688
|
Liabilities
|
|
|
|
Current
liabilities
|
|
|
|
Trade and other
payables
|
|
1,889,258
|
2,584,039
|
Credit
facility
|
|
4,362,850
|
4,823,545
|
Lease
obligations
|
|
106,486
|
544,700
|
Deferred
revenue
|
|
48,185
|
48,185
|
Debentures
|
|
2,550,619
|
2,409,103
|
|
|
8,957,398
|
10,409,572
|
Debentures
|
|
2,762,368
|
1,068,772
|
|
|
11,719,766
|
11,478,344
|
Equity/Deficit
|
|
|
|
Common
shares
|
|
49,385,725
|
47,978,992
|
Contributed
surplus
|
|
14,073,223
|
12,861,449
|
Deficit
|
|
(69,748,658)
|
(66,374,097)
|
|
|
(6,289,710)
|
(5,533,656)
|
|
|
5,430,056
|
5,944,688
|
NEWTOPIA INC.
Condensed Interim Consolidated Statements of
Loss and Comprehensive Loss (Unaudited)
Three and Nine Months Ended September 30,
2023 and 2022
(Expressed in Canadian Dollars)
|
|
|
|
|
|
|
Three Months
Ended
|
|
Nine Months
Ended
|
|
|
September
30,
|
|
September
30,
|
|
|
2023
|
2022
|
|
2023
|
2022
|
|
|
$
|
$
|
|
$
|
$
|
|
|
|
|
|
|
|
Revenue
|
|
2,434,606
|
2,653,411
|
|
7,440,297
|
8,052,111
|
Cost of
revenue
|
|
1,040,988
|
1,201,016
|
|
3,501,663
|
4,060,793
|
Gross profit
|
|
1,393,618
|
1,452,395
|
|
3,938,634
|
3,991,318
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
Technology and
development
|
|
446,504
|
1,259,596
|
|
1,891,276
|
2,909,996
|
Sales and
marketing
|
|
317,544
|
645,452
|
|
1,094,976
|
2,158,597
|
General and
administrative
|
|
814,967
|
1,370,557
|
|
2,714,405
|
3,869,565
|
Share‑based
compensation
|
|
158,584
|
140,314
|
|
466,887
|
404,112
|
Depreciation of
property and
equipment
|
|
1,386
|
11,891
|
|
4,965
|
39,674
|
Depreciation of
right‑of‑use asset
|
|
‑
|
46,192
|
|
‑
|
138,579
|
|
|
1,738,985
|
3,474,002
|
|
6,172,509
|
9,520,523
|
|
|
|
|
|
|
|
Other expenses
(income)
|
|
|
|
|
|
|
Interest and accretion
expense
|
|
246,556
|
79,163
|
|
593,979
|
276,884
|
Interest on lease
obligations
|
|
5,221
|
17,485
|
|
26,784
|
60,747
|
Finance
charges
|
|
145,024
|
70,269
|
|
376,990
|
147,816
|
Amortization of
deferred finance
charges
|
|
39,710
|
68,140
|
|
107,500
|
191,910
|
Foreign exchange
(gain)/loss
|
|
(17,302)
|
(5,534)
|
|
36,791
|
(28,998)
|
Capitalized borrowing
costs
|
|
‑
|
‑
|
|
‑
|
(67,000)
|
Debt
modification
|
|
8,956
|
‑
|
|
8,956
|
‑
|
Loss on settlement of
related party
payable
|
|
(3,111)
|
‑
|
|
(10,314)
|
‑
|
|
|
425,054
|
229,523
|
|
1,140,686
|
581,359
|
Net loss and
comprehensive loss
|
|
(770,421)
|
(2,251,130)
|
|
(3,374,561)
|
(6,110,564)
|
NEWTOPIA INC.
Condensed Interim Consolidated Statements of
Changes in Equity (Deficit) (Unaudited)
Nine Months Ended September 30, 2023
and 2022
(Expressed in Canadian Dollars)
|
|
|
|
|
|
|
Common Shares
|
Contributed Surplus
|
Deficit
|
Total
|
|
|
$
|
$
|
$
|
$
|
|
Balance, December
31, 2022
|
47,978,992
|
12,861,449
|
(66,374,097)
|
(5,533,656)
|
|
Net loss and
comprehensive loss
|
‑
|
‑
|
(3,374,561)
|
(3,374,561)
|
|
Share‑based
compensation
|
‑
|
466,887
|
‑
|
466,887
|
|
Settlement of related
party payable
|
‑
|
182,451
|
‑
|
182,451
|
|
March 2023 private
placement offering, net of issuance costs
|
930,218
|
537,077
|
‑
|
1,467,295
|
|
March 2023 private
placement offering, compensation options
|
(26,443)
|
26,443
|
‑
|
‑
|
|
Exercise of
warrants
|
318,065
|
(59,766)
|
‑
|
258,299
|
|
Bonus Amendment
Shares
|
78,262
|
‑
|
‑
|
78,262
|
|
Bonus Replacement
Shares
|
15,300
|
14,651
|
‑
|
29,951
|
|
Bonus shares issued on
July 2023 Debenture Offering
|
91,331
|
44,031
|
‑
|
135,362
|
|
Balance, September
30, 2023
|
49,385,725
|
14,073,223
|
(69,748,658)
|
(6,289,710)
|
|
Balance, December
31, 2021
|
45,177,120
|
11,652,200
|
(58,673,634)
|
(1,844,314)
|
|
Net loss and
comprehensive loss
|
‑
|
‑
|
(6,110,564)
|
(6,110,564)
|
|
Share‑based
compensation
|
‑
|
404,112
|
‑
|
404,112
|
|
Private Placement
Offering of Units, net of issuance costs
|
2,624,495
|
511,839
|
‑
|
3,136,334
|
|
Compensation options
issued to brokers
|
(83,230)
|
83,230
|
‑
|
‑
|
|
Adjustment of issuance
costs on Debentures
|
‑
|
4,733
|
‑
|
4,733
|
|
Settlement of related
party payable
|
‑
|
87,121
|
‑
|
87,121
|
|
Balance, September
30, 2022
|
47,718,385
|
12,743,235
|
(64,784,198)
|
(4,322,578)
|
|
|
|
|
|
|
|
|
|
|
NEWTOPIA INC.
Condensed Interim Consolidated Statements of
Cash Flows (Unaudited)
Nine Months Ended September 30, 2023
and 2022
(Expressed in Canadian Dollars)
|
|
|
|
|
Nine Months Ended
September 30,
|
|
|
2023
|
2022
|
|
|
$
|
$
|
Cash flows used in
operating activities:
|
|
|
|
Net loss and
comprehensive loss
|
|
(3,374,561)
|
(6,110,564)
|
Items not involving
cash:
|
|
|
|
Depreciation of
property and equipment
|
|
4,965
|
39,674
|
Depreciation of
right‑of‑use asset
|
|
‑
|
138,579
|
Amortization of
intangible asset
|
|
619,537
|
‑
|
Amortization of
deferred finance charges
|
|
107,500
|
191,910
|
Capitalized borrowing
costs
|
|
‑
|
(67,000)
|
Share‑based
compensation
|
|
466,887
|
404,112
|
Accretion
expense
|
|
353,530
|
124,184
|
Interest on lease
obligations
|
|
26,784
|
60,747
|
Debt
modification
|
|
8,956
|
‑
|
Loss on settlement of
related party payable
|
|
(10,314)
|
‑
|
|
|
(1,796,716)
|
(5,218,358)
|
Net change in non‑cash
working capital
|
|
|
|
Trade and other
receivables
|
|
(216,987)
|
(231,205)
|
Inventories
|
|
208,151
|
(260,852)
|
Prepaid expenses and
deposits
|
|
(33,712)
|
55,880
|
Trade and other
payables
|
|
(502,016)
|
1,043,867
|
Deferred
revenue
|
|
‑
|
(10,248)
|
Contract
asset/liability
|
|
174,670
|
(135,034)
|
|
|
(2,166,610)
|
(4,755,950)
|
Cash flows used in
investing activities
|
|
|
|
Purchase of property
and equipment
|
|
(2,548)
|
(3,829)
|
Intangible asset
development costs
|
|
-
|
(985,349)
|
|
|
(2,548)
|
(989,178)
|
Cash flows from
(used in) financing activities:
|
|
|
|
Credit facility
withdrawals
|
|
4,706,984
|
8,028,277
|
Credit facility
repayments
|
|
(5,167,679)
|
(5,478,831)
|
Credit facility
financing costs
|
|
(117,260)
|
(81,831)
|
Repayment of lease
obligations
|
|
(464,998)
|
(281,913)
|
Proceeds from private
placement issuance of Units, net of
issuance costs
|
|
1,467,295
|
3,136,334
|
Proceeds from issuance
of debenture units, net of
transaction costs
|
|
1,746,201
|
‑
|
Repayment of
Debentures
|
|
(30,000)
|
‑
|
Proceeds from exercise
of warrants
|
|
258,299
|
‑
|
|
|
2,398,842
|
5,322,036
|
Increase/(Decrease) in
cash
|
|
229,684
|
(423,092)
|
Cash, beginning of
period
|
|
345,950
|
811,584
|
Cash, end of
period
|
|
575,634
|
388,492
|
___________________________________
|
1
|
Gross profit is defined
as revenue, which is comprised of onboarding Welcome Kit revenue,
ongoing engagement fees and success fees, less cost of sales, which
is comprised of Welcome Kit costs, compensation expense for
Inspirators and care specialists, genetic testing costs and the
amortization of intangible assets. Gross margin percentage is
calculated by dividing gross profit by total revenue for the
defined period. Gross profit is considered by management to be an
integral measure of financial performance and represents the amount
of revenues retained by the Company after incurring direct costs.
However, gross profit is not a recognized measure of profitability
under IFRS. The Company defines Non-IFRS gross profit as gross
profit plus amortization of intangible assets, for a true revenue
less direct cost calculation and an "apples to apples" comparison
vs. prior periods.
|
2
|
Adjusted operating
expenses consist of all cash-based technology, sales and marketing
and administrative expenses. Adjusted operating expense is not a
measure of financial performance under IFRS and should not be
considered a substitute for total operating expenses, which we
believe to be the most directly comparable IFRS measure.
|
3
|
EBITDA stands for
"earnings before interest, tax, depreciation and amortization".
Although a commonly used financial metric, EBITDA is not a measure
of financial performance under IFRS and should not be considered a
substitute for loss from operations which we believe to be the most
directly comparable IFRS measure.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/newtopia-reports-third-quarter-2023-financial-results-301991352.html
SOURCE Newtopia Inc.